Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HRAS Q61L

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HRAS overexpression (2)

HRAS overexpression (2)

›

HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D
HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D	PF-05212384 Sensitive: D – Preclinical PF-05212384 Sensitive : D
HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	HRAS Q61L	Squamous Cell Carcinoma of Head and Neck	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D